137058-17-4

Basic information

• Product Name: Cyclohexanecarboxylic acid, 4-methoxy-, methyl ester
• CAS NO: 137058-17-4
• Molecular Formula: C9H16O3
• Molecular Weight: 172.224
• Mol File: 137058-17-4.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Cyclohexanecarboxylic acid, 4-methoxy-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarboxylic acid, 4-methoxy-, methyl ester(137058-17-4)
• EPA Substance Registry System: Cyclohexanecarboxylic acid, 4-methoxy-, methyl ester(137058-17-4)

Safety Data

• Hazardous Substances Data: 137058-17-4(Hazardous Substances Data)

Upstream product

• 121-98-2 methyl 4-methoxybenzoate 
• 67-56-1 methanol 
• 95233-12-8 4-methoxycyclohexylcarboxylic acid 

Downstream Products

• 213915-20-9 cis-1-benzyloxymethyl-4-methoxycyclohexanecarboxylic acid 
• 101869-74-3 (4-methoxy-cyclohexyl)-methanol 
• 596806-86-9 methyl 1-[hydroxy(mesitylacetyl)amino]-4-methoxycyclohexanecarboxylate 
• 306948-20-9 3-(2,6-dimethyl-phenyl)-4-hydroxy-8-methoxy-1-methoxymethoxy-1-aza-spiro[4.5]dec-3-en-2-one 
• 306948-19-6 3-(2,6-dimethyl-phenyl)-4-hydroxy-1,8-dimethoxy-1-aza-spiro[4.5]dec-3-en-2-one 
• 596806-75-6 methyl 1-(hydroxyamino)-4-methoxycyclohexanecarboxylate 
• 73873-64-0 Methyl 1-methyl-trans-4-methoxycyclohexanecarboxylate 
• 73873-66-2 methyl 1-methyl-cis-4-methoxycyclohexanecarboxylate 
• 95233-12-8 4-methoxycyclohexylcarboxylic acid 
• 73873-59-3 4-methoxycyclohexanecarboxylic acid 
• 73873-61-7 trans-4-methoxycyclohexane-1-carboxylic acid 

Relevant articles and documents

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.

SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

VLA-4 INHIBITORS

The present invention relates to a compound represented by the following formula (I): (wherein, W represents WA-A1 -WB - (in which, WA is substituted or unsubstituted aryl, etc., A1 is -NR1-, single bond, -C(O)-, etc., and WB is substituted or unsubstituted arylene, etc.), R is single bond, -NH-, -OCH2-, alkenylene, etc., X is -C(O) -CH2-, etc., and M is, for example, the following formula: (in which, R11, R12 and R13 each independently represents hydrogen, hydroxyl, amino, halogen, etc., R14 is hydrogen or lower alkyl, Y represents -CH2-O-, etc., Z is substituted or unsubstituted arylene, etc., A2 is single bond, etc, and R10 is hydroxyl or lower alkoxy)), or salt thereof; and a medicament containing the same. This compound or salt thereof selectively inhibits binding of cell adhesion molecules to VAL-4 and exhibits high bioavailability so that it is useful as a preventive and/or remedy for inflammatory diseases, autoimmune diseases, metastasis, bronchial asthma, rhinostenosis, diabetes, and the like.